Adaptive Clinical Protocol Design for Phase II MPox Clade I Treatment with a Novel Broad-Spectrum Drug NV-387 is Almost Complete, Reports NanoViricides

Stock Information for null

Loading

Please wait while we load your information from QuoteMedia.